权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Reducing the environmental impact of Metered Dose Inhalers with aflo, the automated inhaler technique platform

利用自动吸入器技术平台 aflo 减少定量吸入器对环境的影响

基本信息

批准号：
10055368
负责人：
金额：
$ 6.37万
依托单位：
RESPIRATORY ANALYTICS LTD
依托单位国家：
英国
项目类别：
Grant for R&D
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=10055368
关键词：
Reducing environmental impact Metered Dose

项目摘要

Globally, more than 750M people live with asthma and chronic obstructive pulmonary disease (COPD). Uncontrolled symptoms of these conditions cost $34B in the US and £1.5B in the UK annually. Pressurised metered-dose inhalers (MDIs) were introduced in 1956 for the treatment of asthma and COPD, followed by Dry Powder Inhalers (DPIs) in the 1980's. Evidence shows that 86% of inhaler users make at least one technique error and optimising drug delivery to control symptoms remains a world-wide problem. Inexpensive, generic MDIs play a vital role but the propellants they use are a significant contributor to Green House Gases (GHG). A low carbon propellant, HFA 152a is in development, due to be introduced in 2025\.The NHS Net Zero target focused attention on the Global Warming Potential (GWP) of inhalers, identifying a reduction of MDI usage as a policy objective. Recently concerns have been raised about the wider societal and environmental impact of this policy. Emerging evidence (Jeswani et al 2019) suggests the wider environmental impact of DPIs - fossil depletion, terrestrial acidification, marine and freshwater eutrophication, marine and freshwater ecotoxicity - is greater than that of MDIs. The NHS Net Zero policy may have unintended environmental consequences. Additionally, switching MDI users to DPIs carries patient risk. Solutions are needed that address the broader environmental impact, while ensuring patients are not put at risk of losing control of symptoms if inhaler choice is not appropriate.In previous Innovate UK supported research and development, Respiratory Analytics designed and built a deep tech platform, aflo(tm). It automates correct inhaler technique via the integration of a medical grade data capture device, a user co-designed app with real-time feedback, a clinician portal and a cloud-hosted data analytics hub, to improve symptom control and patient self management and to provide quantified clinician remote monitoring.Like many pharmaceutical products there is limited data on the environmental impact of respiratory inhalers. This project seeks to provide primary evidence that automating inhaler technique for MDIs with aflo(tm) will lower the environmental impact of MDIs by optimising drug deposition of lower GWP 'preventer' (corticosteroid) inhalers, controlling symptoms, so reducing the need for high GWP 'reliever' (short acting beta agonist - SABA) inhalers. A second aspect of the research will investigate appropriate disposal/ recycling of MDIs. Our real world inhaler technique project will contribute to the very important emerging body of research into inhaler environmental impacts.

在全球范围内，超过7.5亿人患有哮喘和慢性阻塞性肺疾病（COPD）。这些疾病的不受控制的症状每年在美国花费340亿美元，在英国花费15亿英镑。1956年引入了加压计量吸入器（MDI）用于治疗哮喘和COPD，随后在20世纪80年代引入了干粉吸入器（DPI）。有证据表明，86%的吸入器使用者至少犯了一个技术错误，优化药物输送以控制症状仍然是一个世界性的问题。廉价的通用计量吸入器发挥着至关重要的作用，但它们使用的推进剂是绿色家用气体的重要贡献者。一种低碳推进剂HFA 152 a正在开发中，将于2025年推出。NHS净零目标将注意力集中在吸入器的全球变暖潜能值（GWP）上，将减少MDI的使用作为政策目标。最近，人们对这一政策的更广泛的社会和环境影响表示关切。新出现的证据（Jeswani等人，2019年）表明，DPI的更广泛的环境影响-化石消耗，陆地酸化，海洋和淡水富营养化，海洋和淡水生态毒性-大于MDI。NHS净零政策可能会产生意想不到的环境后果。此外，将MDI用户转换为DPI会给患者带来风险。我们需要解决方案来应对更广泛的环境影响，同时确保患者在吸入器选择不当的情况下不会面临症状失控的风险。在之前的Innovate UK支持的研发中，Respiratory Analytics设计并构建了一个深度技术平台aflo（tm）。它通过集成医用级数据采集设备、用户共同设计的具有实时反馈的应用程序、临床医生门户和云托管数据分析中心，自动化正确的吸入器技术，以改善症状控制和患者自我管理，并提供量化的临床医生远程监测。与许多制药产品一样，呼吸吸入器对环境影响的数据有限。该项目旨在提供主要证据，证明使用aflo（tm）的计量吸入器的自动化吸入器技术将通过优化低全球升温潜能值“预防剂”（皮质类固醇）吸入器的药物沉积、控制症状，从而减少对高全球升温潜能值“缓解剂”（短效β激动剂- SABA）吸入器的需求，降低计量吸入器对环境的影响。研究的第二个方面将调查计量吸入器的适当处置/回收。我们的真实的世界吸入器技术项目将有助于吸入器环境影响研究的非常重要的新兴机构。